Information Provided By:
Fly News Breaks for April 19, 2016
NVTA, MYGN
Apr 19, 2016 | 12:02 EDT
Piper Jaffray analyst William Quirk believes the selloff today in Myriad Genetics (MYGN) over Noridian's preliminary reimbursement rate for CPT code 81432 is unwarranted. Myriad does not currently bill to Medicare using the new 81432 CPT code since it has its own Z-code through MolDx, Quirk tells investors. The analyst, who believes private payers reimburse myRisk at or above Medicare's rate, keeps an Overweight rating on Myriad shares.
News For MYGN;NVTA From the Last 2 Days
There are no results for your query MYGN;NVTA